EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 335-342

  Modjtahedi, Helmout ^a   Affleck, Karen ^b   Stubberfield, Colin ^b   Dean, Christopher ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Epidermal growth factor receptor; Monoclonal antibody; Tyrosine kinase inhibitor

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ICR 63; MONOCLONAL ANTIBODY ICR 80; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

EID: 0031817827     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.335     Document Type: Article

References (43)

1. Thompson DM and Gill GN: The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv 4: 767-788, 1985.
2. Carpenter G: Receptor for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881-914, 1987.
3. Salomon DS, Bradt R, Ciardiello F and Normano N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
4. Vlue TJ: Structure, function and transforming potential of the epidermal growth factor receptor. Mol Cell Endocrinol 70: 205-216, 1990.
5. Earp HS, Dawson TL, Li X and Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signalling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115-132, 1995.
6. Hendler FJ and Ozanne BW: Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74: 647-651, 1984.
7. Cowley G, Smith JA and Gusterson B: The amount of EGF receptor is elevated on squamous cell carcinomas. Cancer Cells 1: 5-10, 1984.
8. Neal DE, Sharples L and Smith K: The epidermal growth factor and the prognosis of bladder cancer. Cancer 65: 1619-1625, 1990.
9. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87-98, 1991.
10. Modjtahedi H and Dean C: The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (Review). Int J Oncol 4: 277-296, 1994.
11. Sporn MB and Roberts AB: Autocrine growth factors and cancers. Nature 313: 745-747, 1985.
12. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molly CJ, Aaronson SA and Di Force PP: Autocrine interaction between TGFα and the EGF-receptor: quantitative requirement for induction of malignant phenotype. Oncogene 4: 831-838, 1989.
13. Morishigie KI, Kurachi H, Amemiya K, Fujita Y, Yamamoto T, Miyake A and Tanizawa O: Evidence for the involvement of TGFα and EGFR autocrine mechanism in primary human ovarian cancers in vitro. Cancer Res 51: 5322-5328, 1991.
14. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato JH: Biological effects in vitro of mAbs to the human EGF receptors. Mol Biol Med 1: 511-514, 1983.
15. Yaish P, Gazit A, Gilon C and Levitzki A: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242: 933-935, 1988.
16. Aboud-Pirak B, Hurwitz E, Bellot F, Schlessinger J and Sela M: Inhibition of human tumour growth in nude mice by conjugate of doxorubicin with monoclonal antibodies to the epidermal growth factor receptor. Proc Natl Acad Sci USA 86: 3778-3781, 1989.
17. Heimbrook DC, Stirdivant SM, Ahern JD, Balishin NL, Patrick DR, Edwards GM, Defesco-Jones D, Fitzgerald DJ, Pastan I and Olief A: Transforming growth factor α-pesudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumour xenografts. Proc Natl Acad Sci USA 87: 4697-4701, 1990.
18. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 266: 21118-21124, 1991.
19. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW and Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265: 1093-1095, 1994.
20. Weis W, Beerli R, Hellman P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B and Hynes N: EGF receptor and p185 specific single-chain antibody toxin differ in their cell-killing activity on tumour cells expressing both receptor proteins, Int J Cancer 60: 137-144, 1995.
21. Chakrabarty S, Rajagopal S and Haung S: Expression of antisense epidermal growth factor receptor RNA down modulates the malignant behaviour of human colon cancer cells. Clin Exp Metastasis 13: 191-195, 1995.
22. Harris AL: The epidermal growth factor receptor as target for therapy. Cancer Cells 2: 321-323, 1990.
23. Workman P, Brunton VG and Robins DJ: Tyrosine kinase inhibitors. Semin Cancer Biol 3: 369-381, 1992.
24. Baselga J and Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29: 127-138, 1994.
25. Davies DE and Chamberlin SG: Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 51: 1101-1110, 1996.
26. Traxler PM: Protein tyrosine kinase inhibitors in cancer treatment. Exp Opin Ther Patents 7: 571-588, 1997.
27. Modjtahedi H, Styles JM and Dean CJ: The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB-468. Br J Cancer 67: 247-253, 1993.
28. Modjtahedi H, Eccles S, Box G, Syles J and Dean C: Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67: 254-261, 1993.
29. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J and Dean C: Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the EGF receptor. Cancer Res 54: 1695-1701, 1994.
30. Wu X, Fan Z, Masui H, Rosen N and Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897-1905, 1995.
31. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, Di Orio C, Doty J, Morin MJ, Moyer MP, Nuveu M, Pollack VA, Pustilnik LR, Reynolds MN, Sloan D, Theleman A and Miller P: Induction of apoptosis and cell cycle arrest by CP-358,774, and inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57: 4838-4848, 1997.
32. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW and Baselga J: PD153035, a tyrosine kinase inhibitor, prevent epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 3: 2099-2106, 1997.
33. Modjtahedi H and Dean C: Antibody inhibition of EGFR overexpressing tumours occurs in the absence of receptor down-regulation. Int J Oncol 7: 783-788, 1995.
34. Modjtahedi H, Cohen B and Dean C: Monoclonal antibodies directed against the EGF receptor show differential bindings of amphiregulin and EGF to the EGF receptor. Int J Oncol 10: 339-347, 1997.
35. Philpott NJ, Turner AJC, Scopes J, Westby M, Marsh JCW, Gordon-Smith EC, Dalgleish AG and Gibson FM: The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 87: 2244-2251, 1996.
36. Johnson N, Ng TTC and Parkin JM: Camptothecin causes cell cycle perturbations within T-lymphoblastoid cells followed by dose dependent induction of apoptosis. Leuk Res 21: 961-972, 1997.
37. Watt FM: Keratinocyte cultures: an experimental model for studying how proliferation and terminal differentiation are coordinated in the epidermis. J Cell Sci 90: 525-529, 1988.
38. Fuchs E: Epidermal differentiation: the bare essentials. J Cell Biol 111: 2807-2814, 1990.
39. Modjtahedi H, Styles J and Dean C: The growth response of human tumour cell lines overexpressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding. Int J Oncol 3: 237-243, 1993.
40. Divigi GR, West S, Kris M, Real FX, Yeh DJ, Gralla R, Merchant B, Scheight S, Unger M, Larson SM and Mendelsohn J: Phase 1 and imaging trial of Indium III-labelled anti-EGF receptor antibody 225 in patients with squamous cell lung carcinomas. J Natl Cancer Inst 83: 97-104, 1991.
41. Bier H, Reiffen KA, Haas I and Stasieki P: Dose-dependence access of murine anti-epidermal growth factor receptor monoclonal antibody to tumour cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol 252: 433-439, 1995.
42. Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C and Gore M: A phase I trial and tumour localization of the anti-EGFR antibody ICR62 in head and neck or lung cancer. Br J Cancer 73: 228-235, 1996.
43. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703-2707, 1997.